placeholder image

K. Park All authors

About

Publications While At HealthPartners
selected publications
Journal Article
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
    Lancet Oncology. 2018
  • Contact
    full name
  • K. Park
  • Quick Info

    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration